The twin focus of this Program Project is drug discovery and clinical development of new anticancer agents being discovered in our laboratories through the Corbett/Valeriote assays. The synthetic compounds and their analogs are obtained from both the inventories and synthetic chemistry laboratories of Lilly Pharmaceutical Company at a rate of 5,000 per year (Core D). These compounds are tested in Core C against the common human drug resistant epithelial tumors: colon, breast and lung. While we expect that a variety of classes of chemotherapeutic agents will be taken to clinical trial, they must first be active against either murine or human tumors both in vitro and in vivo. Extensive in vivo secondary analysis is carried out in appropriate murine and human tumor models. This includes breadth of activity against various tumors, schedule and route analysis and hot recovery and toxicity information. These are done under Corbett's Project. This Project also supports the analysis of analogs of in vivo active agents and concomitant structure-activity relationship studies. The analogs are studied both in vivo and in vitro with emphasis on the tumor types indicated above. Promising compounds will be tested in the clinic in the context of well-controlled Phase I and II trials, focussing on the clinical correlation of our experimental results (Valeriote's Project). The Phase I trials will include patients with any type of tumor resistant to therapy. The Phase II trials will be carried out specifically on those tumors which demonstrated sensitivity in the experimental studies and will be limited to colon, pancreas, breast, ovary, prostate and lung. Another component of this Program is the analysis of both pharmacokinetic data and mechanism of action studies on the compound (Valeriote's Project). The pharmacokinetic information will be used in the Phase I trials to escalate the dose according to new non- Fibronacci schemes which make use of comparative AUC information. Metabolite and excretion studies will also be carried out on the compounds. Specific mechanism of action studies will be done which are amenable to being carried out on patient material. At present, we have a number of chemotherapeutic agents at this stage of development.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA046560-08
Application #
2654034
Study Section
Special Emphasis Panel (SRC (F1))
Program Officer
Xie, Heng
Project Start
1989-05-04
Project End
2000-01-31
Budget Start
1998-02-01
Budget End
2000-01-31
Support Year
8
Fiscal Year
1998
Total Cost
Indirect Cost
Name
Wayne State University
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
City
Detroit
State
MI
Country
United States
Zip Code
48202
Djuric, Zora; Vanloon, Glee; Radakovich, Katherine et al. (2008) Design of a Mediterranean exchange list diet implemented by telephone counseling. J Am Diet Assoc 108:2059-65
Corbett, Thomas H; White, Kathryn; Polin, Lisa et al. (2003) Discovery and preclinical antitumor efficacy evaluations of LY32262 and LY33169. Invest New Drugs 21:33-45
Polin, Lisa; White, Kathryn; Kushner, Juiwanna et al. (2002) Preclinical efficacy evaluations of XK-469: dose schedule, route and cross-resistance behavior in tumor bearing mice. Invest New Drugs 20:13-22
Poondru, Srinivasu; Parchment, Ralph E; Purohit, Vivek et al. (2002) Lack of in vitro-in vivo correlation of a novel investigational anticancer agent, SH 30. Invest New Drugs 20:23-33
Poondru, S; Zhou, S; Rake, J et al. (2001) High-performance liquid chromatographic method for the estimation of the novel investigational anti-cancer agent SR271425 and its metabolites in mouse plasma. J Chromatogr B Biomed Sci Appl 759:175-8
LoRusso, P M; Foster, B J; Wozniak, A et al. (2000) Phase I pharmacokinetic study of the novel antitumor agent SR233377. Clin Cancer Res 6:3088-94
Keyes, K A; Albella, B; LoRusso, P M et al. (2000) Cytotoxic chemotherapy regimens that increase dose per cycle (dose intensity) by extending daily dosing from 5 consecutive days to 28 consecutive days and beyond. Clin Cancer Res 6:2474-81
Corbett, T H; Panchapor, C; Polin, L et al. (1999) Preclinical efficacy of thioxanthone SR271425 against transplanted solid tumors of mouse and human origin. Invest New Drugs 17:17-27
Edelstein, M; Corbett, T; Valeriote, F (1998) In vitro screening model for the detection of agents active against myelogenous leukemia. Cancer Invest 16:303-8
Perni, R B; Wentland, M P; Huang, J I et al. (1998) Synthesis and antitumor activity of 4-aminomethylthioxanthenone and 5-aminomethylbenzothiopyranoindazole derivatives. J Med Chem 41:3645-54

Showing the most recent 10 out of 33 publications